Tenvir-EM Emtricitabine/Tenofovir 200mg/300mg | Cipla India Generic | GLT

Generic Information: Tenvir-EM (India)

Tenvir-EM is Cipla's fixed-dose combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, a WHO-prequalified generic of the originator Truvada. Supplied as thirty blue, capsule-shaped film-coated tablets per bottle, it reproduces the reference two-drug backbone at a fraction of the brand price, which matters for national HIV programs and self-funded patients who depend on affordable long-term supply.

What Is Tenvir-EM Used For?

Tenvir-EM is used in two ways, exactly like the originator. Combined with other antiretrovirals, it treats HIV-1 infection in adults. Taken alone as pre-exposure prophylaxis, it lowers the risk of sexually acquired HIV-1 in people who test HIV-negative. Its WHO prequalification signals that the product meets international standards for quality, safety and efficacy, a reassurance for procurement agencies buying at scale.

How Does Tenvir-EM Work?

Emtricitabine and tenofovir are both reverse transcriptase inhibitors that shut down HIV's genetic copying. Inside infected cells they are phosphorylated into active triphosphate and diphosphate forms that mimic the natural nucleosides the virus needs to build its DNA; when reverse transcriptase grabs one of these lookalikes, the growing chain is terminated and replication stops. The two drugs reinforce each other against a single essential target.

Indications

Tenvir-EM is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults, and for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in at-risk adults. It is not indicated for hepatitis B, and anyone stopping it who is co-infected with HBV needs close monitoring because a hepatitis flare can occur.

Dosage

The recommended dose is one tablet once daily, with or without food. Each tablet delivers 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate. Dose interval is lengthened in moderate renal impairment and the combination is generally avoided at very low creatinine clearance. For PrEP, a confirmed negative HIV test before starting and regular retesting during use are essential safeguards.

Side Effects

Nausea, diarrhea, headache and fatigue are the most frequent early effects and usually settle with continued use. The serious long-term concerns are kidney toxicity and reduced bone mineral density, both driven by tenofovir disoproxil, so renal function is monitored throughout treatment. Lactic acidosis with liver enlargement and post-discontinuation hepatitis B flare are rare but important warnings.

Storage

Tenvir-EM is stored at room temperature in the original container, protected from moisture and light, with no refrigeration required. Ambient-condition shipping keeps the supply chain simple and reliable, and GLT dispatches from a Hong Kong-licensed facility with batch documentation and a certificate of analysis.

Why Choose Tenvir-EM Through GLT?

Cipla's WHO-prequalified combination delivers originator-equivalent emtricitabine/tenofovir at a generic price point, a decisive factor for large-volume procurement and long-duration treatment or PrEP. GLT's Hong Kong base adds documented, traceable cross-border access, helping overseas buyers secure a dependable Indian generic with verified quality credentials.

How to Order

To order Tenvir-EM (emtricitabine/tenofovir disoproxil fumarate) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We confirm stock, pack options and delivery timelines to your country, and dispatch from a Hong Kong-licensed facility.

FAQ

Is Tenvir-EM the same as Truvada? It is a WHO-prequalified generic containing the same two active ingredients in the same strengths as the originator Truvada.

Why choose an Indian generic? Cipla's version offers originator-equivalent dosing at a substantially lower price, important for long-term and large-volume use.

Is it for treatment or prevention? Both — it treats HIV-1 in combination therapy and lowers acquisition risk as PrEP in HIV-negative people.